{
  "id": "everyday#screening_cues_75c8b0f9",
  "title_en": "General — Screening Cues",
  "title_vi": "General — Dấu hiệu sàng lọc",
  "text_en": "(219), mhGAP operations manual (209), will highlight the changes (updates) and the new mhGAP community toolkit (220) and the mhGAP recommendations presented in this guideline. e-learning course, which is being developed with the WHO Academy. The media will be notified of the updated mhGAP guideline. Capacity-building activities will be 4.3 WHO model list of undertaken through regional and subregional essential medicines (EML) meetings and other activities related to mhGAP and implementation of four WHO action plans: the The EML and EMLc includes products for MNS disorders Comprehensive mental health action plan 2021–2030 in the areas of psychotic disorders, mood disorders, (14), the Intersectoral global action plan on epilepsy anxiety, substance use and epilepsy (13,132). The and other neurological disorders 2022–2031 (3), the updated recommendations for any psychotropic Global action plan on the public health response to medicines will be used to inform the EML and EMLc dementia 2017–2025 (15), and the Global alcohol action and to promote affordable access to quality, safe and plan 2022–2030 (16). effective medicines for MNS disorders. 16 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre 112 5. Monitoring and evaluating the impact of the guideline After the publication of this mhGAP guideline, where possible, including the Atlas: country resources WHO will continue to collect regular feedback from for neurological disorders (23), the Comprehensive implementation activities to evaluate their usefulness mental health action plan 2013–2030 (14), the Mental and impact. WHO will additionally continue to collect health atlas 2020 (24), indicators provided as part of feedback from international experts and health workers implementing WHO’s Intersectoral global action plan who are familiar with using the mhGAP guideline. This on epilepsy and other neurological disorders 2022–2031 information will be used to evaluate the effects of the (3), the Global action plan on the public health response guideline on processes and health outcomes and to to dementia 2017–2025 (15) and the Global alcohol ensure the quality of the guideline and identify areas to action plan 2022–2030 (16). be improved. This will draw on existing WHO resources 113",
  "gloss_vi": "(219), mhgap operations manual (209), will highlight the changes (updates) and the new mhgap community toolkit (220) and the mhgap recommendations presented in this guideline. e-learning course, which is being developed ...",
  "source": "Everyday Essentials",
  "url": "",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "screening_cues"
    ],
    "life_topics": [
      "work"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "low"
  },
  "index_text": "General — Screening Cues General — Dấu hiệu sàng lọc (219), mhGAP operations manual (209), will highlight the changes (updates) and the new mhGAP community toolkit (220) and the mhGAP recommendations presented in this guideline. e-learning course, which is being developed with the WHO Academy. The media will be notified of the updated mhGAP guideline. Capacity-building activities will be 4.3 WHO model list of undertaken through regional and subregional essential medicines (EML) meetings and other activities related to mhGAP and implementation of four WHO action plans: the The EML and EMLc includes products for MNS disorders Comprehensive mental health action plan 2021–2030 in the areas of psychotic disorders, mood disorders, (14), the Intersectoral global action plan on epilepsy anxiety, substance use and epilepsy (13,132). The and other neurological disorders 2022–2031 (3), the updated recommendations for any psychotropic Global action plan on the public health response to medicines will be used to inform the EML and EMLc dementia 2017–2025 (15), and the Global alcohol action and to promote affordable access to quality, safe and plan 2022–2030 (16). effective medicines for MNS disorders. 16 https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre 112 5. Monitoring and evaluating the impact of the guideline After the publication of this mhGAP guideline, where possible, including the Atlas: country resources WHO will continue to collect regular feedback from for neurological disorders (23), the Comprehensive implementation activities to evaluate their usefulness mental health action plan 2013–2030 (14), the Mental and impact. WHO will additionally continue to collect health atlas 2020 (24), indicators provided as part of feedback from international experts and health workers implementing WHO’s Intersectoral global action plan who are familiar with using the mhGAP guideline. This on epilepsy and other neurological disorders 2022–2031 information will be used to evaluate the effects of the (3), the Global action plan on the public health response guideline on processes and health outcomes and to to dementia 2017–2025 (15) and the Global alcohol ensure the quality of the guideline and identify areas to action plan 2022–2030 (16). be improved. This will draw on existing WHO resources 113 (219), mhgap operations manual (209), will highlight the changes (updates) and the new mhgap community toolkit (220) and the mhgap recommendations presented in this guideline. e-learning course, which is being developed ..."
}